<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Increased activation of excitatory amino acid (EAA) receptors is considered a major cause of neuronal damage </plain></SENT>
<SENT sid="1" pm="."><plain>Possible sources and mechanisms of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced EAA release were investigated pharmacologically with microdialysis probes placed bilaterally in rat striatum </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and controlled <z:hpo ids='HP_0002615'>hypotension</z:hpo> in <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized rats </plain></SENT>
<SENT sid="3" pm="."><plain>During 30 minutes of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, microdialysate concentrations of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and <z:chebi fb="0" ids="29995">aspartate</z:chebi> were measured in the presence of a nontransportable blocker of the astrocytic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> transporter GLT-1, dihydrokinate (DHK), or an <z:chebi fb="5" ids="22563">anion</z:chebi> channel blocker, 4,4'-dinitrostilben-2,2'-disulfonic acid (<z:chebi fb="0" ids="34663">DNDS</z:chebi>), administered separately or together through the dialysis probe </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In control striata during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and <z:chebi fb="0" ids="29995">aspartate</z:chebi> concentrations increased 44+/-13 (mean+/-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) times and 19+/-5 times baseline, respectively, and returned to baseline values on reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>DHK (1 mmol/L in perfusate; n=8) significantly attenuated EAA increases compared with control (<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> peak, 9 </plain></SENT>
<SENT sid="6" pm="."><plain>6+/-1.7 versus control, 15.4+/-2.6 pmol/ microL) </plain></SENT>
<SENT sid="7" pm="."><plain>EAA levels were similarly decreased by 10 mmol/L DHK </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="34663">DNDS</z:chebi> (1 mmol/L; n=5) also suppressed EAA peak increases (<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> peak, 5.8+/-1.1 versus control, 10.1+/-0.7 pmol/ microL) </plain></SENT>
<SENT sid="9" pm="."><plain>At a higher concentration, <z:chebi fb="0" ids="34663">DNDS</z:chebi> (10 mmol/L; n=7) further reduced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and <z:chebi fb="0" ids="29995">aspartate</z:chebi> release and also inhibited <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:chebi fb="5" ids="15891">taurine</z:chebi> release </plain></SENT>
<SENT sid="10" pm="."><plain>Together, 1 mmol/L DHK and 10 mmol/L <z:chebi fb="0" ids="34663">DNDS</z:chebi> (n=5) inhibited 83% of EAA release (<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> peak, 2.7+/-0.7 versus control, 10.9+/-1.2 pmol/ microL) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These findings support the hypothesis that both cell swelling-induced release of EAAs and reversal of the astrocytic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> transporter are contributors to the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increases of extracellular EAAs in the striatum as measured by microdialysis </plain></SENT>
</text></document>